MPIMalaysian Pharmaceutical
Intelligence
BETALook up
Fields · A10

Diabetes

Biguanide, sulfonylureas, DPP-4 and SGLT2. The older agents are crowded; the SGLT2 class is the newest to reach the register in volume.

18.3%
Prevalence
3,900,000
Estimated patients
43%
On treatment
RM 0.3–2.0B
Market / yr*
Burden: NHMS 2019 (2019) · * Coarse open estimate — NHMS 2019 treated patients × MOH published therapy cost (~1 DDD/day). Order-of-magnitude; precise molecule-level size & market concentration are in the read.
Market structure, at a glance.
The 6 tracked molecules in this field, grouped by makers and patent status. A neutral count — no verdict.
1 generic-open
1 near cliff
4 multi-source
Generic-open — off-patent, generics registeredNear cliff — patent expiry within ~24 monthsMulti-source — 10+ registered makers
Generic-open1 molecule
Glimepiride
7 registered maker(s) · off-patent, generics registered · sulfonylurea
Near cliff1 molecule
Empagliflozin
off-patent 2025 · 3 registered maker(s), market still thin · SGLT2
Multi-source4 molecules
Metformin
37 registered makers · market already open · biguanide
Gliclazide
23 registered makers · market already open · sulfonylurea
Sitagliptin
13 registered makers · market already open · DPP-4
Dapagliflozin
12 registered makers · market already open · SGLT2